A PYMNTS Company

US: Momenta, Amphastar settle generic drug patent case

By  |  June 20, 2019

OnWednesday, Amphastar Pharmaceuticals said Momenta Pharmaceuticals Inc and Novartis AG’s Sandoz unit will pay it $59.9 million to resolve patent and antitrust lawsuits over their dueling generic versions of the blood-thinner Lovenox.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The settlement ends an appeal by Momenta and Sandoz of a Boston federal jury’s 2017 verdict finding that a patent they claimed Amphastar infringed was invalid, a decision that exposed them to losing $100 million that they had posted as a bond earlier in the litigation.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.